Viruses – seeking and destroying the tumor program
Open Access
- 21 November 2005
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 24 (52) , 7640-7655
- https://doi.org/10.1038/sj.onc.1209047
Abstract
DNA viruses have enormous utility in cancer research, both as tools for tumor target discovery as well as agents for lytic cancer therapies. This is because there is a profound functional overlap between the DNA viral and tumor cell programs. DNA viruses encode proteins that elicit growth deregulation in infected cells similar to that engendered by mutations in tumor cells. Evolution has refined viral proteins to target the critical cellular hubs that regulate growth. Thus, viral proteins are discriminating biochemical probes that can be used to identify and characterize novel tumor targets. Moreover, the overlap between the DNA viral and tumor programs can also be exploited for the development of lytic cancer therapies. Discovering whether tumor cells selectively complement the replication of viral mutants can reveal novel oncolytic viral therapies, as well as unexpected tumor properties. For example, altered RNA export was recently uncovered as a novel tumor cell property that underlies ONYX-015 replication, a promising oncolytic adenoviral therapy. A perspective is provided on how adenovirus could be systematically exploited to map the requisite role, or indeed the redundancy, of cellular pathways that act in an integrated program to elicit pathological replication. This knowledge has important applications for the rational design of the next generation of oncolytic viruses, as well as the discovery of efficacious combination cancer therapies.Keywords
This publication has 188 references indexed in Scilit:
- Recent lessons in gene expression, cell cycle control, and cell biology from adenovirusOncogene, 2005
- VSV-tumor selective replication and protein translationOncogene, 2005
- Intrinsic tumour suppressionNature, 2004
- Targeted cancer therapyNature, 2004
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Network biology: understanding the cell's functional organizationNature Reviews Genetics, 2004
- Cell Death: Critical Control PointsPublished by Elsevier ,2004
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Phosphoinositide-3 kinase-PKB/Akt pathway activation is involved in fibroblast Rat-1 transformation by human T-cell leukemia virus type I taxOncogene, 2001
- The Hallmarks of CancerCell, 2000